🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
32.33
+2.54 (8.53%)
Nov 19, 2026, 1:44 PM EST - Market open

UroGen Pharma Statistics

Total Valuation

UroGen Pharma has a market cap or net worth of $1.59 billion. The enterprise value is $1.69 billion.

Market Cap1.59B
Enterprise Value 1.69B

Important Dates

The last earnings date was Wednesday, November 4, 2026, before market open.

Earnings Date Nov 4, 2026
Ex-Dividend Date n/a

Share Statistics

UroGen Pharma has 49.05 million shares outstanding. The number of shares has increased by 5.29% in one year.

Current Share Class 49.05M
Shares Outstanding 49.05M
Shares Change (YoY) +5.29%
Shares Change (QoQ) +0.35%
Owned by Insiders (%) 1.89%
Owned by Institutions (%) 87.10%
Float 43.57M

Valuation Ratios

PE Ratio n/a
Forward PE 18.29
PS Ratio 5.84
Forward PS 3.00
PB Ratio n/a
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 6.26
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.40

Current Ratio 3.40
Quick Ratio 2.81
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -1.75

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -8.46%
Return on Invested Capital (ROIC) -45.18%
Return on Capital Employed (ROCE) -15.64%
Weighted Average Cost of Capital (WACC) 12.53%
Revenue Per Employee $834,177
Profits Per Employee -$219,170
Employee Count300
Asset Turnover 1.10
Inventory Turnover 1.28

Taxes

In the past 12 months, UroGen Pharma has paid $1.60 million in taxes.

Income Tax 1.60M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +38.64% in the last 52 weeks. The beta is 1.64, so UroGen Pharma's price volatility has been higher than the market average.

Beta (5Y) 1.64
52-Week Price Change +38.64%
50-Day Moving Average 35.91
200-Day Moving Average 31.89
Relative Strength Index (RSI) 53.75
Average Volume (20 Days) 1,524,728

Short Selling Information

The latest short interest is 5.11 million, so 10.41% of the outstanding shares have been sold short.

Short Interest 5.11M
Short Previous Month 5.61M
Short % of Shares Out 10.41%
Short % of Float 11.72%
Short Ratio (days to cover) 4.80

Income Statement

In the last 12 months, UroGen Pharma had revenue of $250.25 million and -$65.75 million in losses. Loss per share was -$1.31.

Revenue250.25M
Gross Profit 228.75M
Operating Income -30.94M
Pretax Income -64.15M
Net Income -65.75M
EBITDA -30.63M
EBIT -30.94M
Loss Per Share -$1.31
Full Income Statement

Balance Sheet

The company has $90.55 million in cash and $196.28 million in debt, with a net cash position of -$105.73 million or -$2.16 per share.

Cash & Cash Equivalents 90.55M
Total Debt 196.28M
Net Cash -105.73M
Net Cash Per Share -$2.16
Equity (Book Value) -125.22M
Book Value Per Share -2.55
Working Capital 177.87M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$131.85 million and capital expenditures -$203,000, giving a free cash flow of -$132.05 million.

Operating Cash Flow -131.85M
Capital Expenditures -203,000
Depreciation & Amortization 309,000
Net Borrowing 62.17M
Free Cash Flow -132.05M
FCF Per Share -$2.69
Full Cash Flow Statement

Margins

Gross margin is 91.41%, with operating and profit margins of -12.36% and -26.27%.

Gross Margin 91.41%
Operating Margin -12.36%
Pretax Margin -25.64%
Profit Margin -26.27%
EBITDA Margin -12.24%
EBIT Margin -12.36%
FCF Margin n/a

Dividends & Yields

UroGen Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -5.29%
Shareholder Yield -5.29%
Earnings Yield -4.06%
FCF Yield -9.04%

Analyst Forecast

The average price target for UroGen Pharma is $60.71, which is 87.78% higher than the current price. The consensus rating is "Strong Buy".

Price Target $60.71
Price Target Difference 87.78%
Analyst Consensus Strong Buy
Analyst Count 7
Revenue Growth Forecast (3Y) 90.67%
EPS Growth Forecast (3Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

UroGen Pharma has an Altman Z-Score of -1.78 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -1.78
Piotroski F-Score 2